Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Neurodegenerative Diseases Research Centre, Guy's, King's and St Thomas' School of Biomedical Sciences, King's College, London, United Kingdom. peter.jenner@kcl.ac.uk
Peter
P
Jenner
D000662:Amphetamines / Q000378:metabolism; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D000882:Haplorhini; D006801:Humans; D008658:Inactivation, Metabolic; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D008959:Models, Neurological; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010082:Oxepins / Q000494:pharmacology / Q000627:therapeutic use; D018384:Oxidative Stress; D010293:Pargyline / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D011437:Propylamines / Q000737:chemistry / Q000494:pharmacology; D012642:Selegiline / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000662:Amphetamines; D000978:Antiparkinson Agents; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D010082:Oxepins; D011437:Propylamines; C111178:dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine; C031967:rasagiline; C009054:propargylamine; D012642:Selegiline; D010293:Pargyline